EU moves to block Chinese medical device suppliers from public contracts worth over $5.6M

The European Union just fired its most concrete shot yet in the growing trade standoff with China. The European Commission adopted its first-ever measure under the International Procurement Instrument, or IPI, effectively barring Chinese medical device suppliers from competing for large EU public contracts.

The measure, adopted on June 19, 2025, takes effect on June 30. It applies to public procurement contracts for medical devices valued above 5 million euros net of VAT. Those contracts represent approximately 59% of the total EU medical device procurement market.

What the IPI actually does

The tool was designed to address situations where non-EU countries restrict access to their own public procurement markets while simultaneously competing for lucrative government contracts inside Europe.

The European Commission found that 87% of tenders in China’s medical device sector faced discriminatory barriers that limited access for foreign suppliers.

Companies bidding on EU public contracts can still include Chinese-origin medical devices, but their value cannot exceed 50% of the total contract value. So a hospital supply contract worth 10 million euros could include up to 5 million euros worth of Chinese-made devices, but no more.

The restriction is set for an initial period of five years, with the possibility of a five-year extension.

Why medical devices, and why now

The IPI was adopted into law back in 2022 but had never been deployed. Using it now, against China specifically, represents a shift from theoretical deterrence to active enforcement.

European firms face barriers selling into China’s government procurement market, while Chinese firms compete for European public contracts. The 87% figure on discriminatory tender barriers was the data point that tipped the scales.

What this means for investors and the broader market

For companies operating in the European medical device space, European and non-Chinese international manufacturers gained a significant advantage in bidding for public contracts covering approximately 59% of EU government medical device business.

The 50% threshold means a contract can still include Chinese manufacturing, just not rely on it exclusively. It forces procurement to diversify rather than representing a hard decoupling.

The IPI is a horizontal tool that can be applied to any sector where the Commission finds discriminatory procurement practices in a third country. The precedent is now set, and the mechanism is live.

Disclosure: This article was edited by Editorial Team. For more information on how we create and review content, see our Editorial Policy.